GlassScriptPhysician profile
Ronald D Hart
NPI 1356442032
$60,168.59
in general payments reported to CMS, 2019-2025
71 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,234 · 2020: $3,938 · 2021: $4,721 · 2022: $6,292 · 2023: $4,643 · 2024: $10K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $12K · Travel and Lodging: $4,643 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,145.28 |
| Consulting Fee | $12,087.00 |
| Travel and Lodging | $4,642.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Education | $108.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19,221.13 | 2021-2025 | |
| Esperion Therapeutics, INC. | $6,824.48 | 2020-2025 | Nexletol, Nexlizet |
| Novartis Pharmaceuticals Corporation | $6,299.38 | 2019-2025 | |
| Abbvie INC. | $4,361.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,148.81 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,806.03 | 2019-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,780.90 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Lilly USA, LLC | $1,725.38 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $1,386.23 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $1,371.07 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $1,223.92 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Novo Nordisk INC | $1,129.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,117.09 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,060.90 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $1,030.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.